Rebirth 08: Rise from copycat phones

Chapter 474: Galaxy Pharmaceuticals Reaches the Top
In early July, a piece of news suddenly became popular on the domestic Internet and quickly became the top hot search on many content platforms.

This is a revenue report of companies in the major global medical fields compiled by an analytical agency, and lists the top ten global pharmaceutical companies of the year.

The other nine companies on the list are quite normal. They are all well-known global pharmaceutical companies that enjoy an excellent reputation worldwide, and they are all listed companies.

However, there is a non-listed company on this list. This company is still very young and has only been established for a few years.

At the same time, this is also the only Chinese pharmaceutical company!
Finally, the company directly ranked first in global pharmaceutical revenue, with an exaggerated revenue of 56 billion US dollars, surpassing other pharmaceutical companies to become the world's largest pharmaceutical company in terms of revenue!

It is 'Galaxy Pharmaceuticals'!
In this report, Galaxy Pharmaceuticals has earned more than 17 billion US dollars in revenue in years by relying on "Xylocta", a broad-spectrum anti-cancer drug. In addition, it has acquired more than a dozen domestic and foreign pharmaceutical companies or medical equipment manufacturers in the past one or two years, and these acquired companies have also contributed about billion US dollars in revenue.

In the end, Galaxy Pharmaceuticals became the world's number one pharmaceutical company with a revenue of US$56 billion!

Of course, this revenue is guessed data analyzed and compiled by a third-party statistical agency, not the data released by Galaxy Pharmaceuticals itself... Galaxy Pharmaceuticals is a non-company and a wholly-owned subsidiary of the very unique Galaxy Life, and does not disclose detailed financial reports to the public.

Therefore, outsiders do not have a very accurate idea of ​​how much money Galaxy Pharmaceuticals has made in the past year.

Everyone knows that Galaxy Pharmaceuticals' Xiluokeda is a global hit. It has been launched in more than 100 countries around the world and has been officially approved for listing in dozens of countries or regions. However, Galaxy Pharmaceuticals does not disclose the exact revenue, and outsiders do not know it either!
Today, a third-party analysis agency has collected and collated a large amount of information and estimated that Galaxy Pharmaceutical's revenue is at least over 560 billion US dollars. This has given people a clearer and at the same time extremely shocking understanding of Galaxy Pharmaceutical.

Xiluokeda is so exaggerated, and Galaxy Pharmaceuticals is so profitable?
And in fact, it is true...even the third-party estimates are lower. In fact, according to the financial report of Galaxy Pharmaceuticals that Xu Shenxue received, the company's revenue last year exceeded 60 billion US dollars.

Xiluokeda, the super medicine king, has been a huge success in markets around the world and has no rivals at all!

Among the existing sixteen cancer indications, this drug is the first choice!
In addition, in some research hospitals, many doctors have also conducted research on using Xiluokeda for other cancer patients, and some cancers can also be effectively treated!
There are even cancer patients with other types of cancer that are not indicated for treatment, who will try their best to buy Xiluokeda on their own and take it. Some of them are really effective.

Xiluo Keda's current sixteen indications are only those that have been proven effective in Xiluo Keda's previous clinical trials. Xiluo Keda itself is also conducting more clinical trials on other types of cancer, but the results of the clinical trials will take time.

Until now, Xiluokeda has even become a panacea in the minds of almost all cancer patients... But in fact, it is not. In Galaxy Pharmaceuticals' own clinical trials, it has been proven that Xiluokeda has no obvious therapeutic effect on many types of cancer.

At the same time, clinical experiments have also proved that Xiluokeda has no effect on central nervous system tumors. After taking the drug, the experimental patients did not show any improvement...

There are differences in squamous cell carcinoma types of cancer. It is effective for some cancers but not for others, and it is difficult to explain why.

Finally, the effect on lymphoma-type cancers is also disappointing. It only has a certain effect on a few of them, but has no obvious effect on most lymphoma-type cancers.

At present, according to the clinical trial research conducted by Galaxy Pharmaceuticals in the past two years, it was found that Xiluokeda is most effective for adenocarcinoma type cancer. The initial 16 indications were all adenocarcinoma types. At the same time, clinical trials conducted by many research doctors also mainly targeted non-indication adenocarcinoma.

They are all cancer, but why are there differences in treatment effects for cancers with different pathologies? Some are effective and some are not. Even for different cancers with the same pathology, there are differences in treatment effects... To this day, researchers at Galaxy Pharmaceuticals have been unable to explain this situation!

But no matter what, Xiluokeda is still the most effective and widely adaptable anti-cancer drug in the world.

This also led to the hot sales of Xiluokeda after it was launched in more than 100 countries around the world last year.

In different regions, the price of a course of treatment, that is, a box of thirty tablets of Xiluokeda, ranges from tens of thousands of dollars within the medical insurance system, and is even more expensive outside the medical insurance system, even exceeding one hundred thousand dollars in some places.

The specific price outside of medical insurance needs to be negotiated with Galaxy Pharmaceuticals and local medical insurance companies.

The prices outside of medical insurance depend on local tariffs, operating costs, etc.

Such an expensive drug, with such huge sales volume, has led to a single drug selling for more than 50 billion US dollars worldwide.

This has pushed Galaxy Pharmaceuticals directly to the throne of the world's number one pharmaceutical company... Of course, this first place only refers to revenue. In fact, it is still lagging behind in many aspects such as the number of employees, number of products, industry influence, etc.

After all, Galaxy Pharmaceuticals is extremely dependent on the drug Xiluo Keda. The revenue from other drugs or medical devices is very small, adding up to only about 3 billion US dollars... and most of the revenue is contributed by acquired companies.

From a business operation perspective, this revenue structure is unhealthy and even extremely dangerous. Once any problems arise with Xiluokeda, or a competitor with the same broad-spectrum anti-cancer drug emerges, revenue will quickly be halved, leading to the collapse of the company.

In response to this, Xu Shenxue finalized the path of diversified development for Galaxy Pharmaceuticals last year... developing more types of new drugs, imitating some patented expired drugs with high market demand, and at the same time conducting research in the fields of medical equipment and consumables.

Last year, Galaxy Pharmaceuticals frantically acquired more than a dozen pharmaceutical companies or medical device companies of different types, also based on this strategy.

Now it seems that there is some effect, but not much.

Fang Yulin, CEO of Galaxy Pharmaceuticals, said: "Last year, we launched many research projects on our own, and acquired existing companies to take over their markets and research projects. We have launched more than 100 key projects in total. R&D expenditures reached 12 billion US dollars last year, accounting for 20% of revenue expenditures."

"But because the time is relatively short, there haven't been any obvious research and development results in a short period of time!"

"But there are still prospects, especially in the field of medical equipment. Our MRI equipment project team took advantage of Zhiyun's superconducting material technology and spent more than 2 billion US dollars last year to acquire a domestic MRI medical equipment manufacturer. We then reorganized the subsidiary and invested another 2 billion US dollars in research and development!"

"At present, the research and development progress of our MRI project is relatively smooth, and we expect to launch a new generation of improved 3.0T MRI system to the market this fall."

In MRI equipment, T is often used to represent the technical level. There is no need to delve into it, it can be simply understood as generations!
"The new 3.0T system uses KT120 superconducting material from Zhiyun Group. Its superconducting properties at minus degrees Celsius can make the subsequent operating costs of our MRI system better than those of other manufacturers."

"At the same time, we have also greatly optimized the supply chain and introduced a large number of supply chain companies under Fairy Mountain Holdings and Liuhe Investment, which has greatly improved quality control, imaging quality and manufacturing costs!"

"This 3.0T MRI system has reached the world-class technical level, but our cost is lower and the selling price will be lower, so the cost performance will be very good and its market prospects will be very good!"

"At the same time, we are also gradually applying this series of technological advances and new materials to other mature platforms, such as the 1.5T MRI system, to improve performance while reducing costs, with better cost-effectiveness!"

"The above-mentioned 1.5T and 3.0T MRI systems are also the mainstream equipment in the current MRI market. The demand at home and abroad is very large. We expect the subsequent shipment volume to be relatively large!"

"In addition to technical upgrades and improvements to mature products, our R&D team is also developing a 5.0T MRI system and a 7.0T MRI system!"

"The feedback from the technical department is that there are no practical technical difficulties in the 5.0T MRI system. Although what needs to be done now is the design and integration of the system, which will take some time, we expect to be able to produce commercial products next year!"

"At the same time, we are also conducting research on the most cutting-edge 7.0T nuclear magnetic resonance system. There are some technical difficulties in this regard, but our scientists said that there are no insurmountable technical difficulties. It's just that the design and integration of the system are more complicated and troublesome, and more is required. Maybe we should be able to come up with the first prototype in two or three years!"

"Of course, considering that the future 7.0T and even 5.0T MRI systems will only be used in the field of medical research and a small number of medical applications due to their high prices, it is expected that sales will not be too large, so our main research and development efforts are still concentrated on the 1.5T and 3.0T projects!"

"After all, these two levels of MRI systems are the mainstream in the market, and together they can occupy 99% of the market share!"

"In this regard, we have great technical advantages. First of all, we use the KT120 superconducting material exclusively supplied by Zhiyun Group. We have signed an exclusive use rights agreement with Zhiyun Group for KT120 materials in the field of nuclear magnetic resonance equipment. This material can enable our nuclear magnetic resonance equipment to achieve better performance and lower operating costs!"

Nuclear magnetic resonance is very energy-consuming. For example, the common 1.5T nuclear magnetic resonance system needs to generate a magnetic field of 1.5 Tesla, which requires superconducting materials to generate a strong magnetic field under superconducting conditions.

Superconducting materials require extremely low temperatures to achieve a superconducting state, and to maintain low temperatures, a powerful refrigeration system or heat dissipation system is needed...they actually mean the same thing.

As we all know, refrigeration or cooling systems actually consume a lot of electricity. The air conditioners that we often use in summer are a very typical example.

Nuclear magnetic resonance imaging requires maintaining ultra-low temperatures, and the cooling system consumes a lot of electricity.

The advantage of KT120 material is that it does not require such a low superconducting temperature, and the heat dissipation system is not under such great pressure... To put it bluntly, it can save electricity bills!
Don't think that saving electricity seems to be a bad idea. Once the MRI is turned on, the electricity bill is about 1,500 yuan per day, which is 365 days a year. Based on a ten-year service life, the electricity bill will be five or six million yuan.

A 1.5T MRI costs only around million yuan.

Therefore, if we can save electricity bills and save two to three million based on a ten-year service life, then it will have a considerable cost-effectiveness advantage.

Fang Yulin continued: "Of course, more importantly, we also used artificial intelligence technology to deeply process the images to obtain clearer images!"

"In addition, as a supporting service, our company will soon launch a new artificial intelligence technology for identifying MRI images. We are collecting a large amount of MRI image data and identification data to train our image medical artificial intelligence system. After the training is completed, our medical artificial intelligence system will be able to perform artificial intelligence recognition of MRI images and provide auxiliary suggestions for professional medical personnel!"

"We will launch this system to the market together with our MRI system in the future. It is expected to bring additional technical advantages to our MRI equipment!"

When Fang Yulin talked about this, he focused on explaining the development of Galaxy Pharmaceuticals in the field of medical artificial intelligence.

"With the development of artificial intelligence, we believe that artificial intelligence will also set off a new technological revolution in the medical field, which can be seen in the large-scale applications of Yun AI and GTAI."

"Our company has now begun to deploy and train our medical artificial intelligence based on the newly released GTAI3 at the beginning of this year!"

“We predict that the medical artificial intelligence system will provide new revenue growth for our company!”

"Of course, the collection of a large amount of medical data and subsequent training also takes time and costs. We have cooperated with more than 50 large medical institutions in China to collect and train them!"

The application of artificial intelligence in the medical field has actually existed for a long time. After Zhiyun Group released Yun AI, many people consulted Yun AI on related medical issues, and Yun AI would also give reference answers based on the information it collected and organized.

Although Yun Ai is a powerful system, it is a large-scale general artificial intelligence after all. The data collected and trained in the medical field are all public data. Due to the limitations of the medical data used for training, its medical data is insufficient and not rigorous. No matter how good the algorithm of artificial intelligence is, it must have sufficient data for training... If you don't give it data to learn, how can it learn!

Furthermore, as an artificial intelligence that imitates human thinking, Yun AI can sometimes be ‘too smart’… so smart that it will make up false things to deceive users!
This is the "hallucination" in the field of artificial intelligence... The current Yun AI and GTAI, two large-scale generative AIs of Zhiyun Group, have more or less hallucinations. Even Google's own artificial intelligence with poor performance has this characteristic.

Specifically, in order to be logically consistent, it will exaggerate or even fabricate various reference materials and data.

This is a problem of the data used, the model structure, and the underlying algorithm... No matter how powerful Zhiyun Group's underlying algorithm technology in the field of artificial intelligence is, and no matter how good its model structure is, it still has to rely on a large amount of collected and organized data to train the artificial intelligence model!

This issue is rather complicated to explain in detail, and it can only be said that it is a common defect of generative artificial intelligence technology under current technical conditions.

Therefore, it is unreliable to use a general-purpose large-scale generative AI like Yun AI directly as a doctor...especially when users repeatedly ask and question it, it will often change the initial reasoning results.

However, people at Galaxy Pharmaceuticals still see the application value of artificial intelligence in the medical field.

First, we developed an image medical artificial intelligence to interpret medical images such as MRIs. Now we are preparing to further expand it to other fields to judge and analyze various medical information, and then provide doctors with a reference analysis result.

This kind of professional medical artificial intelligence is not for ordinary people, but for hospitals and doctors. It is designed to reduce the workload of doctors, improve the accuracy of medical diagnosis and treatment, and help doctors to identify and fill in the gaps.

This is also the first typical example of the widespread application of artificial intelligence in all walks of life!

Artificial intelligence is far from being as simple as Yun AI, a super-large general-purpose generative AI. In fact, it can be widely used in many industries, even in traditional manufacturing.

Some manufacturing companies have begun to deploy open source artificial intelligence such as GTAI on their own, and then train it with their own data. After training, they use it to assist their internal work processes and reduce their workload.

This is also the reason why many companies, even some traditional manufacturing industries that seem to have nothing to do with artificial intelligence, purchase APO2600 graphics cards, build small server GPUs, and then deploy local GTAI3!
Although most of Zhiyun Group's APO graphics cards are sold to large high-tech companies, especially Internet companies, a considerable number of APO graphics cards are also purchased by companies from all walks of life to deploy GTAI3 for their internal use.

This is also the core reason why Zhiyun Group chose to open source GTAI... If it is not open source, these companies will not be able to deploy local artificial intelligence. Without deploying local artificial intelligence, they will not be able to obtain highly specialized artificial intelligence suitable for their own use. Simply connecting to Yun AI will not be able to solve these problems.

They can only deploy localized GTAI3 on ​​their own to solve these problems.

As a result, the market demand for APO graphics cards will be even greater.

Open-sourcing the GTAI series of artificial intelligence and then taking the opportunity to sell graphics cards is the core deployment of Zhiyun Group in the field of artificial intelligence in recent years. It is also called by the outside world as the most successful business strategy of Zhiyun Group in recent years!
Relying on open source GTAI, Zhiyun Group has created at least $30 billion in additional APO graphics card revenue each year!

In this big wave, Galaxy Pharmaceuticals also began to purchase APO graphics cards on a large scale, then deployed GTAI3, and then trained their own professional medical artificial intelligence, and regarded it as an important development direction for Galaxy Pharmaceuticals in the next stage.

Xu Shenxue is relatively in agreement with Galaxy Pharmaceutical's development direction in the fields of nuclear magnetic resonance equipment and medical artificial intelligence.

Seeing that Xu Shenxue was in a good mood, Fang Yulin also reported on some developments of Galaxy Pharmaceutical in other fields, such as the imitation of patented drugs and conventional medical consumables.

"The market for generic drugs is still relatively large, and we have invested a lot in this area. We try to gain market share by improving quality and adding layers to the brand. This part is mainly focused on the domestic mid-to-high-end market, and we will not compete with domestic generic drugs in the low-end market!"

Xu Shenxue is still quite concerned about generic drugs. After all, although cutting-edge things are good, Xu Shenxue actually pays more attention to the various generic drugs that ordinary people need in their daily lives.

"As I said before, we need to do a good job in generic drugs and provide consumers with a reliable choice!"

"We also need to do better in the field of consumables and try to lower the prices of some imported consumables as much as possible!"

“When running a business, we should focus on the core business of making money, but we should also do some business that bears social responsibility!”

"We make money by relying on Xiluokeda. Some new drugs and new consumables in the future will be enough for us to make ends meet. Generic drugs, common consumables, and even equipment can be treated as social responsibility businesses. Just maintain a certain level of profit. Don't be too greedy!"

"Also, don't try to get involved in the low-end market. Domestic pharmaceutical companies generally lack funds and technology, and they all rely on these low-end markets to survive. With our size, we shouldn't get involved blindly."

Galaxy Pharmaceuticals has annual revenue of several hundred billion US dollars and R&D investment of over ten billion US dollars. This level of revenue and R&D investment ranks first in the world.

If a giant enterprise of this size lowers its profile and enters the low-end market, it will easily lead to severe market turbulence... and force a large number of mid- and low-end pharmaceutical companies to go bankrupt.

Of course, if Galaxy Pharmaceuticals really does this, it will suffer huge losses!
Even those low-end markets cannot support Galaxy Pharmaceutical's annual revenue of hundreds of billions of dollars and R&D investment of tens of billions of dollars.

When Fang Yulin heard this, he couldn't help but sigh. His boss was really not an ordinary businessman... Ordinary businessmen would never talk about a sense of responsibility or not squeezing out the livelihoods of small and medium-sized enterprises. They would just want to make as much money as possible.

Especially for some larger companies, it is a very common business strategy to use their own technology and capital advantages to sweep away small and medium-sized enterprises and seize more market share.

But my boss just doesn’t do that!

This is not only true in the medical field, but also in other fields... Especially in the field of smart terminals, Xu Shenxue controls two core enterprises, Zhiyun Group and Weiku Electronics. If he is really determined to monopolize the smart terminal market to a large extent, there is a certain possibility that he will squeeze other domestic smart terminal companies to death.

But he didn't do that...On the contrary, he almost opened up to supplying various spare parts to other domestic smart terminal manufacturers.

The company's W series mobile phone SOC, memory chips, flash memory chips, screens and other core components have production capacity that is sufficient for its own use, and the remaining capacity is basically sold for money, and it never holds anyone back.

But it's normal that Fang Yulin doesn't understand...Xu Shenxue has never been involved in a single business or product, he has always been involved in the industrial chain.

This has always been the case in the fields of semiconductors, smart terminals, and smart electric vehicles!

In the medical field, because it is just starting out, there has not been time to expand. At the same time, the medical industry is not easy to develop a large-scale industrial chain model.

After all, he doesn’t run a hospital chain…

He just invested in a private hospital last year, but the hospital itself was not for the medical industry, let alone for making money.

It is simply to provide a better medical environment for myself, my family, and the senior management of the group!

In addition, we also use our own scientific research system to provide some scientific research quotas for some researchers in the medical field, to carry out scientific research in the medical field, and see if we can promote further development in the medical field.

So strictly speaking, the private hospital under Xu Shenxue is a research hospital that mainly conducts scientific research in the medical field. Providing medical services is just a side job, and daily diagnosis and treatment services are only for training top doctors and collecting scientific research materials for scientific research projects!

The medical field is not the focus of Xu Shenxue's career, nor is it even a major business segment. Galaxy Pharmaceutical was just an accident... If it weren't for the accidental creation of Xiluokeda, he wouldn't even have planned to start a pharmaceutical company.

He established Galaxy Pharmaceuticals simply for the drug Xiluokeda... It was like making a plate of dumplings for a dish of vinegar.

The field related to medicine that Xu Shenxue values ​​is actually the field of life and health, that is, Galaxy Life... It aims to extend life and restore youth.

It's not just Xu Shenxue who is like this, many other super-rich people on the planet are like this too!
Although Galaxy Life is owned by Xu Shenxue, its investors in the early years were all a large group of super-rich people!

Even now, it still receives donations from many super-rich people every year!
Even the financial group rivals who fought Xu Shenxue to death donated money to Galaxy Life every year...

After all, they can hate Xu Shenxue and question his character, but they really can't question his ability!

So even though they are clearly competitors, and they even know that if Galaxy Life really produces some remarkable results in the future, Xu Shen will use this result to control and threaten them...but they are still willing to donate money to Galaxy Life every year.

Because they feel that if there is anyone on this earth who can lead a company to break through unknown core technologies in the field of life and health, allowing people to live longer or even achieve immortality... then Xu Shenxue is the one with the highest probability!
If Xu Shenxue breaks the agreement and is unwilling to let them use this technology, then they can just rob it... Who doesn't have a few security companies under their control?

However, the prerequisite for snatching is to make the thing first... and Xu Shenxue is the most likely person to come up with this technology!
So, they still donate money every year!

This is the peculiarity of Galaxy Life... It is clearly a company controlled by Xu Shenxue, but every year it receives a steady stream of financial donations from top consortiums around the world.

At the same time, we can also provide extensive support from various research resources in various places.

This also led to the fact that Galaxy Life's research team is the most internationalized of all the companies under Xu Shenxue, with a large number of scientific researchers from different countries.

Xu Shenxue is also happy to see success. After all, the field of life and health must be developed, and it is extremely difficult. There is no practical hope in the long future.

In this case, it would be great if other consortiums could contribute money to join in the effort.

As for what results there will be in the future, whether to use them to threaten the other party, negotiate, etc., we will talk about it later!
Just like the idea of ​​other heads of consortiums, don't worry about the future, just make the product first... Only after the product is made can we talk about distribution of benefits, negotiation, or even competition.

Now let's all work together!
This led to the emergence of Galaxy Life, an extremely special company.

The birth of Galaxy Life led to the emergence of two companies, Galaxy Security and Galaxy Pharmaceuticals. However, after the separation that year, Galaxy Security now has no direct relationship with Galaxy Life and has evolved into a security company personally controlled by Xu Shenxue.

(End of this chapter)